Context Therapeutics Inc. granted a new employee 30,000 stock options to purchase common stock as an inducement for accepting employment. The options were granted at an exercise price of $0.97 per share and have a 10-year term, vesting over four years. Context Therapeutics is a biopharmaceutical company developing T cell engaging bispecific antibodies for solid tumors, including CTIM-76, CT-95, and CT-202. The company is headquartered in Philadelphia. This press release contains forward-looking statements regarding the company’s product candidates and future prospects. For more information, visit www.contexttherapeutics.com.

Read more at GlobeNewswire: Context Therapeutics Announces Inducement Grant Under